Treating bone metastases with local therapy in a breast cancer patient resulted in decreased pain and prevented fracture

Lytic lesions from bone metastases from breast, lung and prostate carcinomas, are associated with a poor prognosis and significant morbidities that include fracture and debilitating pain. Chemotherapeutics, palliative radiation therapy and surgical intervention are routinely used to treat these lesi...

Full description

Saved in:
Bibliographic Details
Published inPain management (London) Vol. 13; no. 10; pp. 569 - 577
Main Authors Palma, David, Thakur, Nikhil, Loy, Joe C, Margulies, Bryan S
Format Journal Article
LanguageEnglish
Published Future Medicine Ltd 01.10.2023
Subjects
breast cancer
lytic tumor
spinal metastasis
Online AccessGet full text

Cover

More Information
Summary:Lytic lesions from bone metastases from breast, lung and prostate carcinomas, are associated with a poor prognosis and significant morbidities that include fracture and debilitating pain. Chemotherapeutics, palliative radiation therapy and surgical intervention are routinely used to treat these lesions. The ZetaMet™ Bone Graft is a novel antitumorigenic and osteoinductive graft that offers a potential alternative treatment option. ZetaMet is composed of calcium phosphate salts, type-I collagen and the small molecule N-allyl noroxymorphone dihydrate. Here, we report the case of a stage IV breast cancer patient with multiple lytic metastatic lesions to the spine that were successfully treated, which led to a significant reduction in pain and increased quality of life. This outcome demonstrates that a locally administered therapeutic intervention may represent an important alternative for patients with bone metastases that warrants further study.
ISSN:1758-1869
1758-1877
DOI:10.2217/pmt-2023-0069